Cargando…

Tristetraprolin is a novel regulator of BDNF

Brain-derived neurotrophic factor (BDNF) regulates multiple biological processes ranging from central nervous system development and function to neuroinflammation and myogenic differentiation and repair. While coordination of BDNF levels is central in determining the biological outcome, mechanisms i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Anmol, Varendi, Kärt, Peränen, Johan, Andressoo, Jaan-Olle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164675/
https://www.ncbi.nlm.nih.gov/pubmed/25279294
http://dx.doi.org/10.1186/2193-1801-3-502
_version_ 1782334985676521472
author Kumar, Anmol
Varendi, Kärt
Peränen, Johan
Andressoo, Jaan-Olle
author_facet Kumar, Anmol
Varendi, Kärt
Peränen, Johan
Andressoo, Jaan-Olle
author_sort Kumar, Anmol
collection PubMed
description Brain-derived neurotrophic factor (BDNF) regulates multiple biological processes ranging from central nervous system development and function to neuroinflammation and myogenic differentiation and repair. While coordination of BDNF levels is central in determining the biological outcome, mechanisms involved in controlling BDNF levels are not fully understood. Here we find that both short (BDNF-S) and long (BDNF-L) BDNF 3’UTR isoforms contain conserved adenylate- and uridylate rich elements (AREs) that may serve as binding sites for RNA-binding proteins (ARE-BPs). We demonstrate that ARE-BPs tristetraprolin (TTP) and its family members butyrate response factor 1 (BRF1) and 2 (BRF2) negatively regulate expression from both BDNF-S and BDNF-L containing transcripts in several cell-lines and that interaction between TTP and AU-rich region in proximal 5’ end of BDNF 3’UTR is direct. In line with the above, endogenous BDNF mRNA co-immunoprecipitates with endogenous TTP in differentiated mouse myoblast C2C12 cells and TTP overexpression destabilizes BDNF-S containing transcript. Finally, RNAi-mediated knock-down of TTP increases the levels of endogenous BDNF protein in C2C12 cells. Our findings uncover TTP as a novel regulator of BDNF assisting future studies in different physiological and pathological contexts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2193-1801-3-502) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4164675
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-41646752014-10-02 Tristetraprolin is a novel regulator of BDNF Kumar, Anmol Varendi, Kärt Peränen, Johan Andressoo, Jaan-Olle Springerplus Research Brain-derived neurotrophic factor (BDNF) regulates multiple biological processes ranging from central nervous system development and function to neuroinflammation and myogenic differentiation and repair. While coordination of BDNF levels is central in determining the biological outcome, mechanisms involved in controlling BDNF levels are not fully understood. Here we find that both short (BDNF-S) and long (BDNF-L) BDNF 3’UTR isoforms contain conserved adenylate- and uridylate rich elements (AREs) that may serve as binding sites for RNA-binding proteins (ARE-BPs). We demonstrate that ARE-BPs tristetraprolin (TTP) and its family members butyrate response factor 1 (BRF1) and 2 (BRF2) negatively regulate expression from both BDNF-S and BDNF-L containing transcripts in several cell-lines and that interaction between TTP and AU-rich region in proximal 5’ end of BDNF 3’UTR is direct. In line with the above, endogenous BDNF mRNA co-immunoprecipitates with endogenous TTP in differentiated mouse myoblast C2C12 cells and TTP overexpression destabilizes BDNF-S containing transcript. Finally, RNAi-mediated knock-down of TTP increases the levels of endogenous BDNF protein in C2C12 cells. Our findings uncover TTP as a novel regulator of BDNF assisting future studies in different physiological and pathological contexts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2193-1801-3-502) contains supplementary material, which is available to authorized users. Springer International Publishing 2014-09-06 /pmc/articles/PMC4164675/ /pubmed/25279294 http://dx.doi.org/10.1186/2193-1801-3-502 Text en © Kumar et al.; licensee Springer. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Kumar, Anmol
Varendi, Kärt
Peränen, Johan
Andressoo, Jaan-Olle
Tristetraprolin is a novel regulator of BDNF
title Tristetraprolin is a novel regulator of BDNF
title_full Tristetraprolin is a novel regulator of BDNF
title_fullStr Tristetraprolin is a novel regulator of BDNF
title_full_unstemmed Tristetraprolin is a novel regulator of BDNF
title_short Tristetraprolin is a novel regulator of BDNF
title_sort tristetraprolin is a novel regulator of bdnf
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164675/
https://www.ncbi.nlm.nih.gov/pubmed/25279294
http://dx.doi.org/10.1186/2193-1801-3-502
work_keys_str_mv AT kumaranmol tristetraprolinisanovelregulatorofbdnf
AT varendikart tristetraprolinisanovelregulatorofbdnf
AT peranenjohan tristetraprolinisanovelregulatorofbdnf
AT andressoojaanolle tristetraprolinisanovelregulatorofbdnf